Marker Therapeutics Inc (MRKR)

[Rkmatters]

TPIV will likely issue a statement explaining how their technology is different and linking to the study that Knutson and others have done. Hard to say what effect it will have on the stock in the short term. TPIV currently does not have any HER2-neu in testing, but the results of the Phase I which just ended were extremely robust. Their HER2-neu vaccine was meant to move forward to Phase II early next year. I sincerely doubt TPIV will shelf their plans due to GALE's failure, as the reason they even licensed the Mayo technology is has 4x5 times the killing capacity of NeuVax and is meant to be superior in form and function.